Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Status:
Completed
Trial end date:
2020-02-13
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Lenalidomide may stop the growth of cancer cells by blocking blood
flow to the cancer. Giving everolimus together with lenalidomide may be an effective
treatment for lymphoma.
PURPOSE: This phase I/II trial is studying the side effects and best dose of giving
everolimus and lenalidomide together and to see how well they work in treating patients with
relapsed or refractory non-Hodgkin or Hodgkin lymphoma.